Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Journal of Environmental Management|October 18, 2020
Identifying N fertilizer management strategies to reduce ammonia volatilization: Towards a site-specific approachM Mencaroni, N Dal Ferro, J Furlanetto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 10, 2016
Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN studyJ Furlanetto, W Eiermann, F Marmé, et al.
Breast Cancer Research and Treatment|November 28, 2017
Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancerS L Villegas, S Darb-Esfahani, G von Minckwitz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 12, 2022
Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete responseS Loibl, A Schneeweiss, J Huober, et al.
ESMO Open|November 10, 2022
A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE)M Schmidt, K Lübbe, T Decker, et al.
ESMO Open|June 5, 2024
Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopausal patients in PENELOPE-BF Marmé, M Martin, M Untch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 17, 2019
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo studyS Loibl, M Untch, N Burchardi, et al.
European Journal of Cancer (Oxford, England : 1990)|July 6, 2019
Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trialsM Martín, S Loibl, T Hyslop, et al.
Pageof 1